Researchers at MIT and UC San Diego have reported pivotal enhancements in gene editing precision. MIT scientists engineered prime editors with significantly reduced error rates, mitigating insertion and deletion mutations for safer genome editing. In parallel, UC San Diego developed a small nuclear RNA-based editing approach, offering a promising alternative to conventional CRISPR with improved safety profiles. Such advances could accelerate therapeutic applications for genetic diseases by reducing off-target effects and improving efficacy.